Impact of Apixaban on clinical outcome of the patients with Large Vessel Occlusion or stenosis

Impact of Apixaban on clinical outcome of the patients with Large Vessel Occlusion or stenosis - ALVO trial

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000022652

Enrollment

700

Registered

2016-06-08

Start date

2016-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic stroke

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients 20 years and older with acute stroke and treated with oral apixaban within 14 days after onset. 2. Patients who are hospitalized in a period from Oct 1, 2014 to Feb 28, 2018 3. Patients with acute cerebral large vessel occlusion or stenosis (> 50%) 4. Patients with non-valvular atrial fibrillation 5. Patients who are not confirmed ICH by MRI or CT within 24 hours after r-tPA infusion.

Exclusion criteria

Exclusion criteria: 1. Patients who are considered to be ineligible for the study participation by the investigator. 2. Patients who are pregnant or potentially pregnant. 3. Patients who have a history of hypersensitivity to apixaban 4. Patients with hepatic disease having coagulation disorder and clinically important bleeding risk 5. Patients with renal failure (creatinine clearance<15 mL/min) 6. Patients with Active pathological bleeding including intracranial bleeding of any type

Design outcomes

Primary

Measure	Time frame
Death and ischemic/bleeding events within 90 days after disease onset	—

Countries

Japan

Contacts

Public ContactKazutaka Uchida

Hyogo College of Medicine Department of Neurosurgery

alvo@hyo-med.ac.jp+81-798-45-6455

Outcome results